Navigation Links
Transdel Pharmaceuticals Announces Management Reorganization
Date:2/18/2010

from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)2 NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Transdel Pharmaceuticals, Inc.

RELATED LINKS
http://www.transdelpharma.com

'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
2. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
3. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
4. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
5. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
6. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
7. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
8. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
9. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. ISTA Pharmaceuticals Announces 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 14, 2011 Regulus Therapeutics Inc ., a ... medicines targeting microRNAs, today announced that it has added ... The addition of Dr. Hannon, a researcher whose work ... microRNA pathway, increases SAB membership to six pioneers in ...
... Renal Therapies Division of B. Braun Medical ... Plasmat™ Futura System for H.E.L.P. ®   LDL Apheresis ... therapy provides a more easy-to-use system for clinicians ... severe hypercholesterolemia. (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
Cached Medicine Technology:Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 2Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 3Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 4Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board 5B. Braun Renal Therapies Division Announces Availability of Advanced Apheresis Therapy System 2
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... or the "Company") (NASDAQ: TTHI , TSX: TTH) ... at 5:00 P.M. EST to discuss,the Second Quarter fiscal ... Officer of the Company, will host the call. Transition,will ... press release to,be issued prior to the call. In ...
... Florida biochemist says coral-killing ... synthetics harm humans, too, ORLANDO, Fla., Feb. ... Florida biochemist Celia Ferreira, Ph.D.,advises., Scientists have found a link ... sunscreen that wash off swimmers every,year., According to a study ...
... MedThink Communications, an,innovator in medical communications, brand ... by Salix Pharmaceuticals, Inc, in,Morrisville to launch ... an,orally disintegrating form of metoclopramide., Salix ... orally disintegrating,metoclopramide tablet and will bring the ...
... Statement of Matthew L.,Myers President, Campaign for Tobacco-Free ... will begin negotiations on an historic,international treaty to ... products -- a global problem that funds organized ... and,undermines efforts to reduce tobacco use and save ...
... play a key role in the likelihood their patients ... interventions targeting both the provider and the patient are ... particular must take into account patient barriers such as ... discovered. The study is published in the March 15, ...
... Web pages dedicated to disseminating breast cancer information, researchers ... have determined that while most breast cancer data found ... pages featured inaccuracies and sites displaying complementary and alternative ... or misleading health information. , Published in the ...
Cached Medicine News:Health News:Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST 2Health News:Choose Biodegradable Sunscreen to Save Coral Reefs 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 2Health News:U.S. on Sidelines as Nations Launch Negotiations on Treaty to Combat Smuggling, Counterfeiting and Other Illicit Trade in Tobacco Products 3Health News:Provider influence and patient barriers affect use of colorectal cancer screening 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2
Bruns bone curette, 9, oval, solid actagonal handle....
MRI curette, 8.5" overall length....
15" overall length, 5" handle....
9.5" overall length, 4.5" handle....
Medicine Products: